-+ 0.00%
-+ 0.00%
-+ 0.00%

ADC Therapeutics Q3 Adj. EPS $(0.19) Beats $(0.36) Estimate, Sales $16.427M Miss $17.077M Estimate

Benzinga·11/10/2025 12:32:52
Listen to the news
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.36) by 47.51 percent. This is a 32.14 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $16.427 million which missed the analyst consensus estimate of $17.077 million by 3.81 percent. This is a 11.03 percent decrease over sales of $18.464 million the same period last year.